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Use of specific antimicrobials for COVID-19: Should we prescribe them now or wait for more 
evidence? 
 
As the number of Coronavirus disease 2019 (COVID-19) cases worldwide rises exponentially, clinicians 
and healthcare systems are faced with a difficult dilemma. Should they focus on supportive care and 
wait for the results of clinical trials or join other clinicians who are already prescribing specific 
antimicrobials which may be active against the virus?  
 
COVID-19 was initially identified as the cause of an outbreak of infection in Wuhan, China at the end 
of December 2019. Since then, the virus has spread rapidly to most countries in the world and resulted 
in over a million infections and 50,000 deaths as of the 3rd of April 2020.1 Most patients with mild 
disease recover within 1-2 weeks, whilst patients with severe disease may require 3-6 weeks.2 Eighty 
percent of patients have mild infection (often symptoms of an upper respiratory tract infection), 15% 
developed severe illness, and 5% required critical care admissions for organ support.3 Mortality is 
currently estimated to be 1-3%.1 Older patients (> 80 years old) and patients with comorbidity such as 
respiratory disease, diabetes, stroke, cardiac disease and cancer are more likely to die from the 
illness.2 Mortality for a patient admitted to critical care is estimated to be about 50% however this 
may be dependent on access to and quality of critical care services. So far, no vaccine or drug has been 
approved to treat human coronaviruses including COVID-19. In addition, there is no validated clinical 
tool or test to predict patients who are likely to develop complications.  
 
There are currently multiple ongoing trials of specific antimicrobials for treatment and prevention of 
COVID-19. The most common agents proposed are chloroquine, ritonavir boosted lopinavir, ribavirin, 
favipravir, remdesivir, interferon, nitazoxanide.  These agents have been proposed as specific therapy 
for COVID-19 based on previous in vitro evidence of activity against Middle East Coronavirus and 
recent evidence of in vitro activity against COVID-19.,4,5In support of their use, there have been case 
reports and observational studies of patients treated with these therapies who have improved and 
survived. In addition, a small sized controlled trial from France suggested significant improvements in 
viral load in patients treated with hydoxychloroquine and Azithromycin compared to supportive care. 
We eagerly wait to see whether other large trials will validate the results from the French study. 
Interestingly, despite suggestions of good invitro activity a recently published trial of use of ritonavir 
boosted lopinavir in patients from China did not show in improvement in outcomes.  This highlights 
the importance of doing and waiting for results of well conducted clinical trials before widespread use 
of these agents.  
Aanecdotal and uncontrolled data have suggested that early treatment with specific antimicrobials 
may reduce the risk of patients developing severe complications. This has prompted empirical use 
these drugs outside of clinical trials in the hope of preventing patients from developing critical illness 
– eg use of hydroxychloroquine or chloroquine as pre-exposure prophylaxis for at-risk contacts or 
healthcare workers. The desire to ‘do something’ for patients and colleagues is entirely 
understandable in the current pandemic, where conventional treatments have seemed so powerless. 
Moreover, some argue that drugs such as chloroquine have been used to treat infections such as 
malaria and HIV for many years with minimal safety concerns. All these reasons may encourage 
clinicians to prescribe these antimicrobials without restrictions. 
We know that supportive therapy is currently recommended as the mainstay of treatment for 
COVID19. Epidemiological data suggests low mortality rates when high quality supportive care is 
provided for patients with COVID-19.2 Justifying use of experimental treatments outside of clinical 
trials for the majority of patients who have mild disease or no symptoms seems to us overly aggressive, 
 
especially if they are given at high doses which may increase the risk of serious side effects such as 
hepatotoxity and cardiotoxity. Patients with multiple morbidities are also at increased risk of drug 
interactions.  
There is currently no specific approved treatment for COVID-19, nor are there large well conducted 
trials suggesting improvement in outcomes when treated with anti-infective agents. Therefore, the 
mainstay of treatment is supportive. Experimental therapies are being investigated as part of clinical 
trials.  We believe that the widespread use of unproven drugs in desperation to vulnerable individuals 
may cause harm and discourage patients and healthcare providers from participating in clinical trials. 
Without a control group to compare, it is impossible to know whether use of these drugs helps or 
causes harm. We therefore strongly recommended that novel or repurposed use of these is only done 
on compassionate grounds or as part of an ethically approved clinical trial such as the WHO Solidarity 
trial. Despite the pressure to do all possible to save lives during the COVID-19 pandemic, we 
recommend that clinicians and especially Infectious Disease Physicians and clinical pharmacists should 
continue to promote and champion antimicrobial stewardship.  
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